BONESUPPORT announced that the company's antibiotic-eluting bone graft CERAMENT G (Gentamicin) has been used surgically for the first time in patients in the US. The patients treated had bone infection (osteomyelitis) caused by fractures induced by trauma. BONESUPPORT received authorization for CERAMENT G in the management of osteomyelitis from the US Food and Drug Administration (FDA) earlier this year.

The extensive clinical documentation on which the market approval is based, shows that CERAMENT G reduces the risk of recurrent bone infection to 4.3% - ­5.5% versus 13.3% for the current US standard of care, PMMA-beads. CERAMENT G is the first and only FDA authorized combination antibiotic-eluting bone graft.